I share your thoughts! I see this as them being able to clearly identify the minimum dose each patient will respond to.

If they implement this CCR5 density test as a pre-screening to the mono pivotal trial can they deny patients above what they determine to be the upper CCR5 density limit for expected response at 700 mg dose? If so, they may be able to get 100% response rate (post induction phase)!

In the real world (post combo and mono approval) maybe these patients with higher density CCR5 would respond to combo therapy at 700 mg? I'm not sure if this theory holds water with the science minds here, but throwing it out there? I am not sure if HAART drugs reduce CCR5 density (I don't think so, but not sure) or if leronlimab is more effective in higher density patients when combined with HAART drugs? I'm sure someone here knows the answer, but just trying to determine if leronlimab can somehow treat all the R5 tropic patients (~70% HIV population) regardless of CCR5 density levels without doing more than 700 mg dose which would likely require additional trials down the road?